Label Changes for:

Hytrin (terazosin hydrochloride) 1, 2, 5, and 10 mg tablets

July 2009

Changes have been made to the PRECAUTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- July 2009

PRECAUTIONS

Drug Interactions
  • Concomitant administration of Hytrin with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension.
Hide
(web3)